In the claims

1. **(Currently amended)** A compound represented by formula **(I):**



(I)

wherein,

A is either a double bond or a single bond, n is 2 or 3, and each occurrence of R_1 is independently selected from the group consisting of hydrogen, aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl;

R_2-R_{13} each independently are selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkoxy, ~~acyl~~ -C(O)R_8, amino, hydroxy, thio, halogen, cyano, nitro, trifluoromethyl, ~~azido~~ -N_3, ~~imino~~ -C(R_8)=NR_8; -N=C(R_8)$_2$, ~~amido~~ -C(O)N(R_8)$_2$, ~~phosphoryl~~ -Q_2-P(Q_1)(OR_8)$_2$, ~~sulfonyl~~ -SO_2R, silyl ~~group~~, ~~ether~~ -R_9OR_8, ~~alkylthio~~ -SR_8, and ~~carbonyl~~ -CO_2R_8;

R_{14} is selected from the group consisting of ~~ester~~ -R_9C(O)OR, -OC(O)R, O-R_{15}, wherein R_{15} is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, alkenyl, and alkynyl; ~~ketone~~ -R_9(O)CR_8; ~~oxime~~ -C(R_8)=N(OH); carboxylic acid; ~~aldehyde~~ -R_9C(O)H; ~~phosphoryl~~ -Q_2-P(Q_1)(OR_8)$_2$; and silyl;

R_8 represents independently for each occurrence hydrogen, alkyl, alkenyl, alkynyl, or aryl;

R_9 represents independently for each occurrence a bond or an alkyl, alkenyl, alkynyl, or aryl biradical;

Q_1 represents independently for each occurrence S or O; and

Q_2 represents independently for each occurrence O, S, or NR_8;

or a pharmaceutically acceptable salt thereof.

2. **(Currently amended)** The compound of claim 1, wherein one occurrence of R_1 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl; A is a double bond; n = 2; at least one occurrence of R_1 is hydrogen, and the compound is an E (entgegen) or Z (zusammen) isomer; R_2-R_{13} each independently represent hydrogen or alkyl; and R_{14} is ~~an ester~~ $-R_9C(O)OR$ or $-OC(O)R$.

3. **(Previously amended)** The compound of claim 1, wherein one occurrence of R_1 is selected from the group consisting of haloaryl, alkoxy, alkylaryl, polycyclyl, alkenylaryl, and alkynylaryl; and either one or two occurrences of R_1 represent hydrogen.

4. **(Previously amended)** The compound of claim 1, wherein A is a double bond; n = 2; and one occurrence of R_1 is selected from the group consisting of phenyl, 3,4-Dichloro-phenyl, 4-methoxy-phenyl, 4-fluoro-phenyl, 1-napthyl, 2-furyl, 3-furyl, methoxy, and substituted or unsubstituted alkenylaryl, and the second occurrence of R_1 is hydrogen, and the compound is an E (entgegen) isomer.

5. **(Currently amended)** The compound of claim 1, wherein one occurrence of R_1 is 4-methoxy-phenyl, one occurrence of R_1 is hydrogen; R_2-R_{13} each represent hydrogen; and R_{14} represents ~~an ester~~ $-R_9C(O)OR$ or $-OC(O)R$.

6. **(Currently amended)** The compound of claim 1, wherein one occurrence of R_1 is phenyl, one occurrence of R_1 is hydrogen, R_2-R_{13} each represent hydrogen, and R_{14} represents ~~an ester~~ $-R_9C(O)OR$ or $-OC(O)R$.

7. **(Currently amended)** A pharmaceutical composition comprising a compound of formula **(I):**



(I)

wherein,

A is either a double bond or a single bond, n is 2 or 3, and each occurrence of R_1 is independently selected from the group consisting of hydrogen, aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl;

R_2-R_{13} each independently are selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkoxy, ~~acyl~~ $-C(O)R_8$, amino, hydroxy, thio, halogen, cyano, nitro, trifluoromethyl, ~~azido~~ $-N_3$, ~~imino~~ $-C(R_8)=NR_8$; $-N=C(R_8)_2$, ~~amido~~ $-C(O)N(R_8)_2$, ~~phosphoryl~~ $-Q_2-P(Q_1)(OR_8)_2$, ~~sulfonyl~~ $-SO_2R$, silyl ~~group~~, ~~ether~~ $-R_9OR_8$, ~~alkylthio~~ $-SR_8$, and ~~carbonyl~~ $-CO_2R_8$;

R_{14} is selected from the group consisting of ~~ester~~ $-R_9C(O)OR$, $-OC(O)R$, $O-R_{15}$, wherein R_{15} is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, alkenyl, and alkynyl; ~~ketone~~ $-R_9(O)CR_8$; ~~oxime~~ $-C(R_8)=N(OH)$; carboxylic acid; ~~aldehyde~~ $-R_9C(O)H$; ~~phosphoryl~~ $-Q_2-P(Q_1)(OR_8)_2$; and silyl;

R_8 represents independently for each occurrence hydrogen, alkyl, alkenyl, alkynyl, or aryl;

R_9 represents independently for each occurrence a bond or an alkyl, alkenyl, alkynyl, or aryl biradical;

Q_1 represents independently for each occurrence S or O; and

Q_2 represents independently for each occurrence O, S, or NR_8;

or a pharmaceutically acceptable salt thereof; and

a pharmaceutically acceptable carrier.

8. **(Currently amended)** The pharmaceutical composition of claim 7, wherein one occurrence of R_1 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl; A is a double bond; n = 2; at least one occurrence of R_1 is hydrogen, and the compound is an E (entgegen) or Z (zusammen) isomer; and R_2-R_{13} each independently represent hydrogen or alkyl; and R_{14} is ~~an ester~~ $-R_9C(O)OR$ or $-OC(O)R$.

9. **(Previously amended)** The pharmaceutical composition of claim 7, wherein one occurrence of R_1 is selected from the group consisting of haloaryl, alkoxy, alkylaryl, polycyclyl, alkenylaryl, and alkynylaryl; and one or two occurrences of R_1 represent hydrogen.

10. **(Previously amended)** The pharmaceutical composition of claim 7, wherein A is a double bond; n = 2; and one occurrence of R_1 is selected from the group consisting of phenyl, 3,4-Dichloro-phenyl, 4-methoxy-phenyl, 4-fluoro-phenyl, 1-napthyl, 2-furyl, 3-furyl, methoxy, and substituted or unsubstituted alkenylaryl, and the second occurrence of R_1 is hydrogen, and the compound is an E (entgegen) isomer.

11. **(Currently amended)** A method for treating a disorder caused by a deficiency in monoamine concentration in a human comprising administering a therapeutically effective dose of a compound of formula **(I)**:



(I)

wherein,

A is either a double bond or a single bond, n is 2 or 3, and each occurrence of R_1 is independently selected from the group consisting of hydrogen, aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl;

R_2-R_{13} each independently are selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkoxy, ~~acyl~~ -C(O)R_8, amino, hydroxy, thio, halogen, cyano, nitro, trifluoromethyl, ~~azido~~ -N_3, ~~imino~~ -C(R_8)=NR_8; -N=C(R_8)$_2$, ~~amido~~ -C(O)N(R_8)$_2$, ~~phosphoryl~~ -Q_2-P(Q_1)(OR_8)$_2$, ~~sulfonyl~~ -SO_2R, silyl ~~group~~, ~~ether~~ -R_9OR_8, ~~alkylthio~~ -SR_8, and ~~carbonyl~~ -CO_2R_8;

R_{14} is selected from the group consisting of ~~ester~~ -R_9C(O)OR, -OC(O)R, O-R_{15}, wherein R_{15} is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, alkenyl, and alkynyl; ~~ketone~~ -R_9(O)CR_8; ~~oxime~~ -C(R_8)=N(OH); carboxylic acid; ~~aldehyde~~ -R_9C(O)H; ~~phosphoryl~~ -Q_2-P(Q_1)(OR_8)$_2$; and silyl;

R_8 represents independently for each occurrence hydrogen, alkyl, alkenyl, alkynyl, or aryl;

R_9 represents independently for each occurrence a bond or an alkyl, alkenyl, alkynyl, or aryl biradical;

Q_1 represents independently for each occurrence S or O; and

Q_2 represents independently for each occurrence O, S, or NR_8;

or a pharmaceutically acceptable salt thereof.

12. **(Currently amended)** The method of claim 11, wherein one occurrence of R_1 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl; A is a double bond; n = 2; at least one occurrence of R_1 is hydrogen, and the compound is an E (entgegen) or Z (zusammen) isomer; and R_2-R_{13} each independently represent hydrogen or alkyl; and R_{14} is ~~an ester~~ -R_9C(O)OR or -OC(O)R.

13. **(Previously amended)** The method of claim 11, wherein one occurrence of R_1 is selected from the group consisting of haloaryl, alkoxy, alkylaryl, polycyclyl, alkenylaryl, and alkynylaryl; and one or two occurrences of R_1 represent hydrogen.

14. **(Previously amended)** The method of claim 11, wherein A is a double bond; n = 2; and one occurrence of R_1 is selected from the group consisting of phenyl, 3,4-Dichloro-phenyl, 4-methoxy-phenyl, 4-fluoro-phenyl, 1-napthyl, 2-furyl, 3-furyl, methoxy, and substituted or unsubstituted alkenylaryl, and the second occurrence of R_1 is hydrogen, and the compound is an E (entgegen) isomer.

15. **(Previously amended)** The method of claim 11, wherein said disorder in a human is associated with a deficiency in the concentration of serotonin or norepinephrine.

16. **(Previously amended)** The method of claim 11, wherein said disorder in a human is selected from the group consisting of depression, substance addiction, neurodegenerative disease, Attention Deficit Disorder, Huntington's Disease, and bipolar disorder.

17. **(Previously amended)** The method of claim 16, wherein said disorder in a human is Parkinson's Disease or Alzheimer's Disease.

18. **(Previously amended)** The method of claim 16, wherein said substance addiction is cocaine addiction.

Claims 19-26. **(Cancelled)**

27. **(Currently amended)** A compound represented by formula **(II):**



(II)

wherein,

R_1 and R_2 each independently are selected from the group consisting of hydrogen, aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl;

R_3-R_{13} each independently are selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkoxy, ~~acyl~~ -C(O)R_8, amino, hydroxy, thio, halogen, cyano, nitro, trifluoromethyl, ~~azido~~ -N_3, ~~imino~~ -C(R_8)=NR_8; -N=C(R_8)$_2$, ~~amido~~ -C(O)N(R_8)$_2$, ~~phosphoryl~~ -Q_2-P(Q_1)(OR_8)$_2$, ~~sulfonyl~~ -SO_2R, silyl ~~group~~, ~~ether~~ -R_9OR_8, ~~alkylthio~~ -SR_8, and ~~carbonyl~~ -CO_2R_8;

R_{14} is selected from the group consisting of ~~ester~~ -R_9C(O)OR, -OC(O)R, O-R_{15}, wherein R_{15} is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, alkenyl, and alkynyl; ~~ketone~~ -R_9(O)CR_8; ~~oxime~~ -C(R_8)=N(OH); carboxylic acid; ~~aldehyde~~ -R_9C(O)H; ~~phosphoryl~~ -Q_2-P(Q_1)(OR_8)$_2$; and silyl;

R_8 represents independently for each occurrence hydrogen, alkyl, alkenyl, alkynyl, or aryl;

R_9 represents independently for each occurrence a bond or an alkyl, alkenyl, alkynyl, or aryl biradical;

Q_1 represents independently for each occurrence S or O; and

Q_2 represents independently for each occurrence O, S, or NR_8;

or a pharmaceutically acceptable salt thereof.

28. (**Currently amended**) The compound of claim 27, wherein R_1 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl, and R_2 is hydrogen, or R_2 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl, and R_1 is hydrogen, and the compound is an E (entgegen) or Z (zusammen) isomer; R_3-R_{13} each independently represent hydrogen or alkyl; and R_{14} is ~~an ester~~ -R_9C(O)OR or -OC(O)R.

29. (**Previously amended**) The compound of claim 27, wherein R_1 is selected from the group consisting of haloaryl, alkoxy, alkylaryl, polycyclyl, alkenylaryl, and alkynylaryl; and R_2 is hydrogen; or R_2 is selected from the group consisting of haloaryl, alkoxy, alkylaryl, polycyclyl, alkenylaryl, and alkynylaryl; and R_1 is hydrogen.

30. (**Previously amended**) The compound of claim 27, wherein R_1 is selected from the group consisting of phenyl, 3,4-Dichloro-phenyl, 4-methoxy-phenyl, 4-fluoro-phenyl, 1-napthyl, 2-furyl, 3-furyl, methoxy, and substituted or unsubstituted alkenylaryl; and R_2 is hydrogen, and the compound is an E (entgegen) isomer.

31. (**Currently amended**) The compound of claim 27, wherein R_1 is 4-methoxy-phenyl, R_2 is hydrogen, R_3-R_{13} each represent hydrogen, and R_{14} is ~~an ester~~ $-R_9C(O)OR$ or $-OC(O)R$.

32. (**Currently amended**) The compound of claim 27, wherein R_1 is phenyl, R_2 is hydrogen, R_3-R_{13} each represent hydrogen, and R_{14} is ~~an ester~~ $-R_9C(O)OR$ or $-OC(O)R$.

33. (**Currently amended**) A pharmaceutical composition comprising a compound of formula **(II)**:



(II)

wherein,

R_1 and R_2 each independently are selected from the group consisting of hydrogen, aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl;

R_3-R_{13} each independently are selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkoxy, ~~acyl~~ $-C(O)R_8$, amino, hydroxy, thio, halogen, cyano, nitro, trifluoromethyl, ~~azido~~ $-N_3$, ~~imino~~ $-C(R_8)=NR_8$; $-N=C(R_8)_2$, ~~amido~~ $-C(O)N(R_8)_2$, ~~phosphoryl~~ $-Q_2-P(Q_1)(OR_8)_2$, ~~sulfonyl~~ $-SO_2R$, silyl ~~group~~, ~~ether~~ $-R_9OR_8$, ~~alkylthio~~ $-SR_8$, and ~~carbonyl~~ $-CO_2R_8$;

R_{14} is selected from the group consisting of ~~ester~~ $-R_9C(O)OR$, $-OC(O)R$, $O-R_{15}$, wherein R_{15} is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, alkenyl, and alkynyl; ~~ketone~~ $-R_9(O)CR_8$; ~~oxime~~ $-C(R_8)=N(OH)$; carboxylic acid; ~~aldehyde~~ $-R_9C(O)H$; ~~phosphoryl~~ $-Q_2-P(Q_1)(OR_8)_2$; and silyl;

R_8 represents independently for each occurrence hydrogen, alkyl, alkenyl, alkynyl, or aryl;

R_9 represents independently for each occurrence a bond or an alkyl, alkenyl, alkynyl, or aryl biradical;

Q_1 represents independently for each occurrence S or O; and

Q_2 represents independently for each occurrence O, S, or NR_8;

or a pharmaceutically acceptable salt thereof; and

a pharmaceutically acceptable carrier.

34. (**Currently amended**) The pharmaceutical composition of claim 33, wherein R_1 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl, and R_2 is hydrogen, or R_2 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl, and R_1 is hydrogen, and the compound is an E (entgegen) or Z (zusammen) isomer; R_3-R_{13} each independently represent hydrogen or alkyl; and R_{14} is ~~an ester~~ $-R_9C(O)OR$ or $-OC(O)R$.

35. (**Previously amended**) The pharmaceutical composition of claim 33, wherein R_1 is selected from the group consisting of haloaryl, alkoxy, alkylaryl, polycyclyl, alkenylaryl, and alkynylaryl; and R_2 is hydrogen; or R_2 is selected from the group consisting of haloaryl, alkoxy, alkylaryl, polycyclyl, alkenylaryl, and alkynylaryl; and R_1 is hydrogen.

36. (**Previously amended**) The pharmaceutical composition of claim 33, wherein R_1 is selected from the group consisting of phenyl, 3,4-Dichloro-phenyl, 4-methoxy-phenyl, 4-fluoro-phenyl, 1-napthyl, 2-furyl, 3-furyl, methoxy, and substituted or unsubstituted alkenylaryl; and R_2 is hydrogen, and the compound is an E (entgegen) isomer.

37. **(Currently amended)** A method for treating a disorder caused by a deficiency in monoamine concentration in a human comprising administering a therapeutically effective dose of a compound of formula **(II)**:



(II)

wherein,

R_1 and R_2 each independently are selected from the group consisting of hydrogen, aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl;

R_3-R_{13} each independently are selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkoxy, ~~acyl~~ -$C(O)R_8$, amino, hydroxy, thio, halogen, cyano, nitro, trifluoromethyl, ~~azido~~ -N_3, ~~imino~~ -$C(R_8)=NR_8$; -$N=C(R_8)_2$, ~~amido~~ -$C(O)N(R_8)_2$, ~~phosphoryl~~ -Q_2-$P(Q_1)(OR_8)_2$, ~~sulfonyl~~ -SO_2R, silyl ~~group~~, ~~ether~~ -R_9OR_8, ~~alkylthio~~ -SR_8, and ~~carbonyl~~ -CO_2R_8;

R_{14} is selected from the group consisting of ~~ester~~ -$R_9C(O)OR$, -$OC(O)R$, O-R_{15}, wherein R_{15} is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, alkenyl, and alkynyl; ~~ketone~~ -$R_9(O)CR_8$; ~~oxime~~ -$C(R_8)=N(OH)$; carboxylic acid; ~~aldehyde~~ -$R_9C(O)H$; ~~phosphoryl~~ -Q_2-$P(Q_1)(OR_8)_2$; and silyl;

R_8 represents independently for each occurrence hydrogen, alkyl, alkenyl, alkynyl, or aryl;

R_9 represents independently for each occurrence a bond or an alkyl, alkenyl, alkynyl, or aryl biradical;

Q_1 represents independently for each occurrence S or O; and

Q_2 represents independently for each occurrence O, S, or NR_8;

or a pharmaceutically acceptable salt thereof.

38. (**Currently amended**) The method of claim 37, wherein R_1 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl, and R_2 is hydrogen, or R_2 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl, and R_1 is hydrogen, and the compound is an E (entgegen) or Z (zusammen) isomer; R_3-R_{13} each independently represent hydrogen or alkyl; and R_{14} is ~~an ester~~ - $R_9C(O)OR$ or -$OC(O)R$.

39. (**Previously amended**) The method of claim 37, wherein either R_1 is selected from the group consisting of haloaryl, alkoxy, alkylaryl, polycyclyl, alkenylaryl, and alkynylaryl; and R_2 is hydrogen; or R_2 is selected from the group consisting of haloaryl, alkoxy, alkylaryl, polycyclyl, alkenylaryl, and alkynylaryl; and R_1 is hydrogen.

40. (**Previously amended**) The method of claim 37, wherein R_1 is selected from the group consisting of phenyl, 3,4-Dichloro-phenyl, 4-methoxy-phenyl, 4-fluoro-phenyl, 1-napthyl, 2-furyl, 3-furyl, methoxy, and substituted or unsubstituted alkenylaryl; and R_2 is hydrogen, and the compound is an E (entgegen) isomer.

41. (**Previously amended**) The method of claim 37, wherein said disorder in a human is associated with a deficiency in the concentration of serotonin or norepinephrine.

42. (**Previously amended**) The method of claim 37, wherein said disorder in a human is selected from the group consisting of depression, substance addiction, neurodegenerative disease, Attention Deficit Disorder, Huntington's Disease, and bipolar disorder.

43. (**Previously amended**) The method of claim 42, wherein said disorder in a human is Parkinson's Disease or Alzheimer's Disease.

44. (**Previously amended**) The method of claim 42, wherein said substance addiction is cocaine addiction.

Claims 45-59. (**Cancelled**)